wards treatment individualisation according to prognostic risk group.
Until recently, it was accepted that the standard of care for patients with LAHNC was concomitant cisplatin-based chemoradiotherapy. However, recent data on prognostic subgroups suggest that this is a significant oversimplification: patients with poor prognosis disease may receive suboptimal treatment, while those with good prognosis disease may be overtreated with unnecessary risks of toxicity. Therefore, there has been a realignment towards developing effective, molecularly targeted strategies that offer personalised treatment to individual patients based on prognostic factors. The clearest view of prognosis comes from post hoc analysis of patients with oropharyngeal cancers treated in the RTOG-0129 phase III trial [7] . This study defined prognostic groups using specific demographic, clinical/radiological and molecular pathological characteristics: (1) poor-risk disease affected 27% of patients with heavy tobacco use, T4 tumours and HPV/p16
INK4a -negative status; (2) low-risk disease occurred in 43% with HPV-positive status and little prior tobacco exposure (or, if >10 pack-year smoking history, by N0-N2a nodal status) and (3) intermediate-risk disease was represented by the 30% with either HPVpositive tumours and >10 pack-year tobacco exposure and N2b/N3 neck disease or HPV-negative tumours and <10 packyear tobacco exposure and T2/T3 tumours. A particularly attractive approach to targeted therapy focuses on developing combinations of radiotherapy or chemoradiotherapy with targeted agents that modulate RIDDR to exploit differences between malignant and normal tissues. Mutations in p53 have been reported in many LAHNC and correlate with exposure to tobacco/alcohol. p53-mutant LAHNC show relative resistance to radiation, as evidenced by increased locoregional recurrence rates after radical or adjuvant irradiation [9] , and reactivation of p53 has been shown to increase responses to radiation/chemoradiation. In addition, abnormalities in DNA repair signalling involving ataxia-telangiectasia mutated (ATM) and meiotic recombination 11 (MRE11) upstream of p53 are associated with radioresistance.
In contrast, HPV-positive LAHNC does not harbour disruptive p53 mutations but, rather, p53 is inactivated by HPV-E6 [10] . In both situations, functional loss of the p53 pathway renders tumour cells reliant on effective G2/M cell cycle checkpoint control (Fig. 1) . Also, the importance of repair of single-strand DNA breaks, especially in the context of deficiencies in homologous recombination, is well recognised, and targeting this pathway has been shown to increase the response of head and neck cancer cells to radiation in vitro and in vivo [11] .
There is now significant experience in translational preclinical/clinical studies of small molecules and biological agents in LAHNC. In newly-diagnosed LAHNC, agents that target cell cycle checkpoint kinase 1 (Chk1) and heat shock protein-90 (HSP90) have provided proof-of-principle for the potential radiosensitising effects of modulating DNA damage responses at the G2/M checkpoint. Chk1 is key in cellular responses to DNA damage and replication stress. It is phosphorylated in an ataxia telangiectasia-mutated-and Rad3-related-(ATR-)dependent manner that is required to trigger the G2/M checkpoint and promote homologous recombination. Studies have demonstrated enhancement of radiation-induced cytotoxicity through Chk1 inhibition, but none has been with drugs that have yet entered the clinic [12, 13] . HSP90 is a ubiquitously expressed molecular chaperone that exists in a larger complex including HSP70 and co-chaperones (Cdc37, p23, AHA1, Hip and Hop) [14] . HSP90 maintains the conformation of a pool of client proteins that regulate many cell functions. Critically, this includes several signalling molecules and oncogenic proteins that play key roles in cell cycle arrest, DNA damage repair and apoptosis in response to radiotherapy, and a potential advantage of HSP90-targeted therapies lies in their simultaneous combinatorial depletion of many components of the RIDDR. Preclinical HSP90-mediated radiosensitisation has been reported with geldanamycin, its derivatives (17-N-allylamino-17-demethoxygeldanamycin (17-AAG), 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)), the PU3 purine scaffold derivative BIIB021, and with NVP-AUY922 [15] . In the context of relapsed/metastatic disease, EGFR-targeted therapies have been shown to yield improved outcomes. In addition, a new class of therapies based on replication-competent, oncolytic viruses has entered clinical trials and shown significant promise [16] .
In summary, our improved knowledge of the molecular biology of LAHNC has revealed that specific disease subtypes may be amenable to personalised treatment approaches. The challenge for the next decade is to optimise these treatments to improve antitumour effects and to minimise toxic effects in normal tissues.
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